HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencing

Virology

Volumn 474, Issue , 2015, Pages 34-40

  Carter, Christoph C ^a   Wagner, Gabriel A ^a   Hightower, George K ^a   Caballero, Gemma ^b   Phung, Pham ^c   Richman, Douglas D ^a,b   Pond, Sergei L Kosakovsky ^a   Smith, Davey M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

Author keywords

HIV 1 genetic diversity; Neutralizing antibody; Neutralizing antibody breadth and potency; Next generation sequencing; Viral evolution

Indexed keywords

NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENVELOPE GENE; GAG GENE; GENE IDENTIFICATION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NEXT GENERATION SEQUENCING; NONHUMAN; SCORING SYSTEM; SEQUENCE ANALYSIS; SPECIES DIVERSITY; STRUCTURAL GENE; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS NEUTRALIZATION; BIOSYNTHESIS; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LONGITUDINAL STUDY; TIME FACTOR; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, NEUTRALIZING; COHORT STUDIES; GENES, ENV; GENES, GAG; GENES, POL; GENETIC VARIATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; LONGITUDINAL STUDIES; TIME FACTORS;

EID: 84909606569     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.10.019     Document Type: Article

References (37)

1. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nystrom G., Fenyo E.M. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990, 4:107-112.
2. Bailey J., Blankson J.N., Wind-Rotolo M., Siliciano R.F. Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. Curr. Opin. Immunol. 2004, 16:470-476.
3. Barouch D.H., Whitney J.B., Moldt B., Klein F., Oliveira T.Y., Liu J., Stephenson K.E., Chang H.-W., Shekhar K., Gupta S., Nkolola J.P., Seaman M.S., Smith K.M., Borducchi E.N., Cabral C., Smith J.Y., Blackmore S., Sanisetty S., Perry J.R., Beck M., Lewis M.G., Rinaldi W., Chakraborty A.K., Poignard P., Nussenzweig M.C., Burton D.R. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013, 503(7475):224-228.
4. Butler D.M., Delport W., Kosakovsky Pond S.L., Lakdawala M.K., Cheng P.M., Little S.J., Richman D.D., Smith D.M. The origins of sexually transmitted HIV among men who have sex with men. Sci. Transl. Med. 2010, 2:18re11.
5. Carotenuto P., Looij D., Keldermans L., de Wolf F., Goudsmit J. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998, 12:1591-1600.
6. Cortez V., Odem-Davis K., McClelland R.S., Jaoko W., Overbaugh J. HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS Pathog. 2012, 8:e1002611.
7. Deeks S.G., Schweighardt B., Wrin T., Galovich J., Hoh R., Sinclair E., Hunt P., McCune J.M., Martin J.N., Petropoulos C.J., Hecht F.M. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J. Virol. 2006, 80:6155-6164.
8. Doria-Rose N.A., Klein R.M., Daniels M.G., O'Dell S., Nason M., Lapedes A., Bhattacharya T., Migueles S.A., Wyatt R.T., Korber B.T., Mascola J.R., Connors M. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 2010, 84:1631-1636.
9. Euler Z., van den Kerkhof T.L., van Gils M.J., Burger J.A., Edo-Matas D., Phung P., Wrin T., Schuitemaker H. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J. Virol. 2012, 86:2045-2055.
10. Frost S.D., Wrin T., Smith D.M., Pond S.L.K., Liu Y., Paxinos E., Chappey C., Galovich J., Beauchaine J., Petropoulos C.J. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. USA 2005, 102:18514-18519.
11. Geffin R., Hutto C., Andrew C., Scott G.B. A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. Virology 2003, 310:207-215.
12. Gianella S., Delport W., Pacold M.E., Young J.A., Choi J.Y., Little S.J., Richman D.D., Kosakovsky Pond S.L., Smith D.M. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J. Virol. 2011, 85:8359-8367.
13. Kendall M.G. Rank Correlation Methods. N.Y. 1990, Oxford University Press. 5th ed.
14. Klein F., Halper-Stromberg A., Horwitz J.A., Gruell H., Scheid J.F., Bournazos S., Mouquet H., Spatz L.A., Diskin R., Abadir A., Zang T., Dorner M., Billerbeck E., Labitt R.N., Gaebler C., Marcovecchio P.M., Incesu R.B., Eisenreich T.R., Bieniasz P.D., Seaman M.S., Bjorkman P.J., Ravetch J.V., Ploss A., Nussenzweig M.C. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492:118-122.
15. Klein F., Mouquet H., Dosenovic P., Scheid J.F., Scharf L., Nussenzweig M.C. Antibodies in HIV-1 vaccine development and therapy. Science 2013, 341:1199-1204.
16. Le T., Wright E.J., Smith D.M., He W., Catano G., Okulicz J.F., Young J.A., Clark R.A., Richman D.D., Little S.J., Ahuja S.K. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N. Engl. J. Med. 2013, 368(3):218-230.
17. Mascola J.R., Haynes B.F. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 2013, 254:225-244.
18. Medina-Ramirez M., Sanchez-Merino V., Sanchez-Palomino S., Merino-Mansilla A., Ferreira C.B., Perez I., Gonzalez N., Alvarez A., Alcocer-Gonzalez J.M., Garcia F., Gatell J.M., Alcami J., Yuste E. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J. Virol. 2011, 85:5804-5813.
19. Mikell I., Sather D.N., Kalams S.A., Altfeld M., Alter G., Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011, 7.
20. Moore J.P., Cao Y., Ho D.D., Koup R.A. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J. Virol. 1994, 68:5142-5155.
21. Noviello C.M., Pond S.L., Lewis M.J., Richman D.D., Pillai S.K., Yang O.O., Little S.J., Smith D.M., Guatelli J.C. Maintenance of Nef-mediated modulation of major histocompatibility complex class I and CD4 after sexual transmission of human immunodeficiency virus type 1. J. Virol. 2007, 81:4776-4786.
22. Pacold M., Smith D., Little S., Cheng P.M., Jordan P., Ignacio C., Richman D., Pond S.K. Comparison of methods to detect HIV dual infection. AIDS Res. Hum. Retroviruses 2010, 26:1291-1298.
23. Pacold M.E., Pond S.L., Wagner G.A., Delport W., Bourque D.L., Richman D.D., Little S.J., Smith D.M. Clinical, virologic, and immunologic correlates of HIV-1 intraclade B dual infection among men who have sex with men. AIDS 2012, 26:157-165.
24. Phillips R.E., Rowland-Jones S., Nixon D.F., Gotch F.M., Edwards J.P., Ogunlesi A.O., Elvin J.G., Rothbard J.A., Bangham C.R., Rizza C.R., et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991, 354:453-459.
25. Piantadosi A., Panteleeff D., Blish C.A., Baeten J.M., Jaoko W., McClelland R.S., Overbaugh J. Breadth of neutralizing antibody response to human immunodeficiency virus Type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 2009, 83:10269-10274.
26. Piantadosi A., Chohan B., Panteleeff D., Baeten J.M., Mandaliya K., Ndinya-Achola J.O., Overbaugh J. HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response. AIDS 2009, 23.
27. Piantadosi A., Chohan B., Panteleeff D., Baeten J.M., Mandaliya K., Ndinya-Achola J.O., Overbaugh J. HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response. AIDS 2009, 23:579-587.
28. Pond S.L., Frost S.D., Muse S.V. HyPhy: hypothesis testing using phylogenies. Bioinformatics 2005, 21:676-679.
29. Richman D.D., Wrin T., Little S.J., Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 2003, 100:4144-4149.
30. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., Yu X., Wood B., Self S., Kalams S., Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 2009, 83:757-769.
31. Simek M.D., Rida W., Priddy F.H., Pung P., Carrow E., Laufer D.S., Lehrman J.K., Boaz M., Tarragona-Fiol T., Miiro G., Birungi J., Pozniak A., McPhee D.A., Manigart O., Karita E., Inwoley A., Jaoko W., Dehovitz J., Bekker L.G., Pitisuttithum P., Paris R., Walker L.M., Poignard P., Wrin T., Fast P.E., Burton D.R., Koff W.C. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 2009, 83:7337-7348.
32. Wagner G.A., Pacold M.E., Vigil E., Caballero G., Morris S.R., Kosakovsky Pond S.L., Little S.J., Richman D.D., Gianella S., Smith D.M. Using ultradeep pyrosequencing to study HIV-1 coreceptor usage in primary and dual infection. J. Infect. Dis. 2013, 208:271-274.
33. Wagner G.A., Pacold M.E., Kosakovsky Pond S.L., Caballero G., Chaillon A., Rudolph A.E., Morris S.R., Little S.J., Richman D.D., Smith D.M. Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J. Infect. Dis. 2014, 209:1032-1038.
34. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., PGP Investigators, Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
35. Walker L.M., Simek M.D., Priddy F., Gach J.S., Wagner D., Zwick M.B., Phogat S.K., Poignard P., Burton D.R. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 2010, 6:e1001028.
36. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.-P., Wang S.-K., Ramos A., Chan-Hui P.-Y., Moyle M., Mitcham J.L., Hammond P.W., Olsen O.A., Phung P., Fling S., Wong C.-H., Phogat S., Wrin T., Simek M.D., Investigators P.G.P., Koff W.C., Wilson I.A., Burton D.R., Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2012, 477:466-470.
37. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.